At Clayton plant, Grifols produces first batch of potential COVID-19 treatment | WRAL TechWire

Grifols employs more than 1,500 workers at its Clayton manufacturing facility. The 77-year-old company based in Barcelona, Spain, works in the fields of transfusion, blood banking, protein therapeutics and laboratory analysis. (This work is licensed under a Creative Commons International License.)

At Clayton plant, Grifols produces first batch of potential COVID-19 treatment

Grifols, a global biotherapeutics company with major operations in North Carolina, has delivered the first batches of a therapeutic product manufactured in Clayton that could help prevent and treat COVID-19 infection.